Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer

Combined Aurora kinase A (AURKA) and WEE1 inhibition demonstrates synergistic antitumor effect in squamous cell carcinoma of the head and neck

(2019) Jong Woo Lee et al.   CLINICAL CANCER RESEARCH

The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors

(2018) Leslie A. Parsels et al.   CELL CYCLE

The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer

(2018) Alice Lallo et al.   CLINICAL CANCER RESEARCH

Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis

(2018) Dongshao Chen et al.   Biomed Research International

Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

(2018) Juan Jin et al.   NEOPLASIA

AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations

(2018) Xiangbing Meng et al.   Cancers

Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models

(2018) Anna Capasso et al.   ANTI-CANCER DRUGS

Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer

(2017) Anastasia A. Ionkina et al.   Frontiers in Oncology

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

(2016) Suzanne Leijen et al.   JOURNAL OF CLINICAL ONCOLOGY

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

(2016) Stacey Bagby et al.   Jove-Journal of Visualized Experiments

Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation

(2015) Sophia X. Pfister et al.   CANCER CELL

The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma

(2015) J. L. Pokorny et al.   CLINICAL CANCER RESEARCH

Comparative Effectiveness Analysis of Monotherapy With Cytotoxic Agents in Triple-negative Metastatic Breast Cancer in a Community Setting

(2015) George Dranitsaris et al.   CLINICAL THERAPEUTICS

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

(2015) Khanh Do et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2015) Peter A. Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer

(2015) J. J. Tentler et al.   MOLECULAR CANCER THERAPEUTICS

Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways

(2015) M. Aarts et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

(2014) M. D. Burstein et al.   CLINICAL CANCER RESEARCH

Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study

(2014) Aki Morikawa et al.   NEURO-ONCOLOGY

Efficient Induction of Apoptosis by Wee1 Kinase Inhibition in Hepatocellular Carcinoma Cells

(2014) Tomomi Kogiso et al.   PLoS One

Tumour selective targeting of cell cycle kinases for cancer treatment

(2013) Marieke Aarts et al.   CURRENT OPINION IN PHARMACOLOGY

Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line

(2013) KATSUYUKI TAKAHASHI et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

(2010) Hiroshi Hirai et al.   CANCER BIOLOGY & THERAPY

Evolution of Capecitabine Dosing in Breast Cancer

(2010) Michael Naughton   Clinical Breast Cancer

Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer

(2009) Carey K. Anders et al.   Clinical Breast Cancer